Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2016, Article ID 5215824, 2 pages
http://dx.doi.org/10.1155/2016/5215824
Editorial

The Current State of Cell Therapies for Cerebrovascular Diseases

1Institute of Clinical Medicine-Neurology, University of Eastern Finland, 70210 Kuopio, Finland
2Neurology, Neurocenter, University Hospital of Kuopio, 70210 Kuopio, Finland
3Instituto de Biofísica Carlos Chagas Filho, Federal University of Rio de Janeiro, 21941-902 Rio de Janeiro, RJ, Brazil
4D’Or Institute of Research and Education, 22281-100 Rio de Janeiro, RJ, Brazil
5Fraunhofer Research Institution for Marine Biotechnology, 23562 Lübeck, Germany
6Institute for Medical and Marine Biotechnology, University of Lübeck, 23562 Lübeck, Germany
7Institute of Biomedical Sciences, Federal University of Rio de Janeiro, 21941-902 Rio de Janeiro, RJ, Brazil
8Department of Radiology, Federal University of Rio de Janeiro, 21941-902 Rio de Janeiro, RJ, Brazil

Received 19 August 2016; Accepted 21 August 2016

Copyright © 2016 Jukka Jolkkonen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Lozano, M. Naghavi, K. Foreman et al., “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease study 2010,” The Lancet, vol. 380, no. 9859, pp. 2095–2128, 2013. View at Google Scholar
  2. V. L. Feigin, M. H. Forouzanfar, R. Krishnamurthi et al., “Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010,” The Lancet, vol. 383, no. 9913, pp. 245–254, 2014. View at Google Scholar
  3. R. K. Burt, Y. Loh, W. Pearce et al., “Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases,” The Journal of the American Medical Association, vol. 299, no. 8, pp. 925–936, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. M. Lalu, L. McIntyre, C. Pugliese et al., “Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials,” PLoS ONE, vol. 7, no. 10, Article ID e47559, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Boltze, A. Arnold, P. Walczak, J. Jolkkonen, L. Cui, and D.-C. Wagner, “The dark side of the force—constraints and complications of cell therapies for stroke,” Frontiers in Neurology, vol. 6, article 155, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. G. S. Gonzales-Portillo, S. Reyes, D. Aguirre, M. M. Pabon, and C. V. Borlongan, “Stem cell therapy for neonatal hypoxic-ischemic encephalopathy,” Frontiers in Neurology, vol. 5, article 147, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. T. C. Burns, C. M. Verfaillie, and W. C. Low, “Stem cells for ischemic brain injury: a critical review,” Journal of Comparative Neurology, vol. 515, no. 1, pp. 125–144, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. S. I. Savitz, “Developing cellular therapies for stroke,” Stroke, vol. 46, no. 7, pp. 2026–2031, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. S. A. Mitsialis and S. Kourembanas, “Stem cell-based therapies for the newborn lung and brain: possibilities and challenges,” Seminars in Perinatology, vol. 40, no. 3, pp. 138–151, 2016. View at Publisher · View at Google Scholar · View at Scopus